

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 August 2025 (14.08.2025)



(10) International Publication Number
WO 2025/171006 A1

(51) International Patent Classification:
C07K 16/24 (2006.01)

(21) International Application Number:
PCT/US2025/014593

(22) International Filing Date:
05 February 2025 (05.02.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/550,110 06 February 2024 (06.02.2024) US
63/550,233 06 February 2024 (06.02.2024) US
63/550,382 06 February 2024 (06.02.2024) US
63/573,721 03 April 2024 (03.04.2024) US
63/573,741 03 April 2024 (03.04.2024) US
63/573,893 03 April 2024 (03.04.2024) US
63/574,165 03 April 2024 (03.04.2024) US
63/697,429 20 September 2024 (20.09.2024) US
63/706,462 11 October 2024 (11.10.2024) US

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicant: **PARAGON THERAPEUTICS, INC.**
[US/US]; 221 Crescent Street, Building 23, Suite 105,
Waltham, Massachusetts 02453 (US).

(72) Inventors: **KWAN, Byron Hua**; c/o PARAGON THER-
APEUTICS, INC., 221 Crescent Street, Building 23, Suite
105, Waltham, Massachusetts 02453 (US). **SHAHEEN,
Hussam Hisham**; c/o PARAGON THERAPEUTICS,
INC., 221 Crescent Street, Building 23, Suite 105, Waltham,
Massachusetts 02453 (US).

(74) Agent: **DYKEMAN, David** et al.; Greenberg Traurig, LLP,
One International Place, Suite 2000, Boston, Massachusetts
02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN,
WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: IL-23 BINDING PROTEIN COMPOSITIONS AND METHODS OF USE

(57) Abstract: IL-23 binding proteins (e.g., antibodies) and methods of use, including methods of treating inflammatory bowel disease (e.g., ulcerative colitis or Crohn's disease) comprising administering IL-23 binding proteins.

WO 2025/171006 A1